Skip to main content

Saturn Medic

Clinical Cases

Hemophilia A & B

Clinical Subject Page

Also called

Factor VIII & Factor IX Deficiency

ICD-10

D66- D67

Specialty

Hematology

Onset

Chronic

Reviewed

August 2026
On This Page

Overview

Hemophilia A is caused by factor VIII deficiency, while Hemophilia B is caused by factor IX deficiency. Both are usually X-linked recessive disorders, so they predominantly affect males. The severity depends on the residual clotting factor activity.

Etiology & Risk Factors

-Etiology

Hemophilia A

Caused by mutations in the F8 gene, resulting in reduced or absent factor VIII activity.

Hemophilia B

Caused by mutations in the F9 gene, resulting in reduced or absent factor IX activity.

Inheritance

Both are usually:

  • X-linked recessive

  • Mainly affect males

  • Females may be carriers

  • Rarely, females can have clinically significant disease

-Risk Factors

  • Family history

  • Maternal carrier status

  • Male sex

  • De novo mutation

  • Consanguinity may be relevant in rare familial cases

Pathophysiology

Factor VIII or IX deficiency → impaired intrinsic coagulation pathway → reduced activation of factor X → reduced thrombin generation → inadequate fibrin formation → defective secondary hemostasis → prolonged bleeding and recurrent bleeding into joints, muscles, and deep tissues.

Clinical Presentation

-Symptoms

  • Easy bruising

  • Prolonged bleeding after injury

  • Prolonged bleeding after surgery

  • Recurrent joint bleeding

  • Muscle hematomas

  • Nosebleeds

  • Oral bleeding

  • Hematuria

  • Gastrointestinal bleeding

Hemarthrosis

Commonly affects:

  • Knees

  • Ankles

  • Elbows

Repeated hemarthroses can cause chronic hemophilic arthropathy.

-Severe Disease

Severe hemophilia may present during infancy or early childhood with:

  • Spontaneous bleeding

  • Joint bleeding

  • Muscle hematomas

  • Intracranial hemorrhage

Hemophilia A & B Overview
Hemophilia A & B Overview

History Taking

-Ask about:

  • Previous bleeding episodes
  • Joint swelling or pain
  • Muscle hematomas
  • Prolonged bleeding after dental procedures
  • Surgical bleeding
  • Bleeding after circumcision
  • Intracranial bleeding
  • Hematuria
  • Family history
  • Maternal carrier status
  • Previous factor replacement
  • Inhibitor development

Physical Examination

-General Examination

Look for:

  • Pallor

  • Bruising

  • Signs of anemia

-Joint Examination

Assess for:

  • Swelling

  • Warmth

  • Tenderness

  • Reduced range of motion

  • Chronic joint deformity

Common joints:

  • Knee

  • Ankle

  • Elbow

-Muscle Examination

Look for:

  • Muscle swelling

  • Tenderness

  • Reduced movement

  • Signs of compartment syndrome

-Neurological Examination

Assess urgently for:

  • Headache

  • Altered consciousness

  • Focal neurological deficits

  • Signs of intracranial hemorrhage

Investigations

-Complete Blood Count

Usually:

  • Platelet count: normal

  • Hemoglobin may be reduced if significant bleeding has occurred

PT

Usually: Normal

aPTT Typically: Prolonged

Mixing Study

A prolonged aPTT that corrects with normal plasma supports a clotting factor deficiency.

Failure to correct suggests an inhibitor.

Factor Assays

  • Low factor VIII → Hemophilia A

  • Low factor IX → Hemophilia B

Inhibitor Testing

Patients receiving repeated factor replacement may develop factor VIII or IX inhibitors.

-The Bethesda assay can quantify inhibitor levels.

-Genetic Testing

Can identify the causative mutation and is useful for:

  • Confirming diagnosis

  • Carrier testing

  • Family counseling

  • Prenatal diagnosis

Diagnosis

Diagnosis is based on:

  • Compatible bleeding history
  • Family history
  • Prolonged aPTT
  • Normal PT
  • Normal platelet count
  • Reduced factor VIII or IX activity
  • Genetic testing when required

Management

1. Factor Replacement

Hemophilia A

Replace factor VIII.

Options include:

  • Recombinant factor VIII

  • Extended half-life factor VIII preparations

Hemophilia B

Replace factor IX.

Options include:

  • Recombinant factor IX

  • Extended half-life factor IX preparations

Factor replacement is used for:

  • Acute bleeding

  • Surgical procedures

  • Trauma

  • Prevention of recurrent bleeding

2. Emicizumab

Used primarily for Hemophilia A, particularly for routine prophylaxis.

It is a bispecific antibody that mimics the function of factor VIII in the coagulation pathway.

3. Desmopressin

Useful in selected patients with:

  • Mild Hemophilia A

It increases endogenous factor VIII and von Willebrand factor.

It is not useful for Hemophilia B.

4. Antifibrinolytic Therapy

Examples:

  • Tranexamic acid

  • Aminocaproic acid

Particularly useful for:

  • Dental procedures

  • Oral bleeding

  • Mucosal bleeding

5. Inhibitors

If significant factor inhibitors develop, management may include:

  • Bypassing agents

  • Emicizumab for Hemophilia A

  • Immune tolerance induction in selected patients

Complications

  • Recurrent hemarthrosis
  • Chronic hemophilic arthropathy
  • Muscle hematomas
  • Intracranial hemorrhage
  • Gastrointestinal bleeding
  • Urinary tract bleeding
  • Compartment syndrome
  • Inhibitor development
  • Transfusion-related complications in older treatment eras
  • Chronic pain
  • Disability

Prognosis

With modern factor replacement, prophylaxis, and comprehensive specialist care, people with hemophilia can have near-normal life expectancy and good quality of life. The major long-term concerns are recurrent bleeding, joint damage, and development of factor inhibitors.

Key Points / Clinical Pearls

  • Hemophilia A = factor VIII deficiency.
  • Hemophilia B = factor IX deficiency.
  • Both are usually X-linked recessive.
  • They cause deep tissue bleeding and hemarthrosis.
  • PT is normal.
  • aPTT is prolonged.
  • Platelet count is usually normal.
  • Factor assays confirm the deficient clotting factor.
  • Hemophilia A may respond to desmopressin when mild.
  • Emicizumab is an important prophylactic option for Hemophilia A.
  • Hemophilia B is treated with factor IX replacement.
  • Inhibitors are an important complication of factor replacement.
  • Early treatment of bleeding helps prevent permanent joint damage.
  •  
Test yourself

Practice Hemophilia A & B questions

Lock in what you just read with exam-style MCQs and active-recall flashcards from Saturn Medic.

More in Hematology System Clinical Cases

SaturnMedic